In vitro susceptibility testing versus in vivo effectiveness

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Pharmacology

Background:

• The clinical utility of antimicrobial susceptibility testing (AST) has historically been limited by poor correlation with in vivo treatment outcomes.
• Host and pathogen factors significantly influence clinical effectiveness, often independent of AST results.
• Traditional AST methods faced challenges in predicting real-world therapeutic success.

Purpose of the Study:

• To evaluate the enhanced clinical relevance of modern antimicrobial susceptibility testing.
• To explore the impact of pharmacodynamic and pharmacokinetic advancements on AST interpretation.
• To assess the improved correlation between in vitro data and in vivo effectiveness.

Main Methods:

• Review of advancements in understanding pharmacokinetic/pharmacodynamic (PK/PD) parameters.
• Analysis of the integration of PK/PD indices with AST data.
• Evaluation of updated breakpoint methodologies in clinical microbiology.

Main Results:

• Improved understanding of PK/PD parameters has enhanced antimicrobial agent utilization.
• Integration of PK/PD indices significantly strengthens the correlation between in vitro susceptibility and in vivo clinical outcomes.
• Modern clinical microbiology laboratories utilize advanced methods and realistic breakpoints.

Conclusions:

• Antimicrobial susceptibility testing is increasingly clinically relevant due to improved methodologies.
• Pharmacokinetic and pharmacodynamic principles are crucial for bridging the gap between in vitro results and clinical efficacy.
• Realistic breakpoints, informed by PK/PD data, enhance the predictive value of AST for patient treatment.